CHRISTOPHER KAMPFE: Open Payments
NPI 1154333045 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,181 in 99 payments from 26 companies in 2025. Trend: 2023 $2,159 · 2024 $1,647 · 2025 $2,181
Food & beverage: $2,181
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $403 |
| Lilly USA, LLC | 12 | $162 |
| Axsome Therapeutics, Inc. | 6 | $160 |
| Boston Scientific Corporation | 1 | $142 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 18 | $141 |
| Gilead Sciences, Inc. | 2 | $125 |
| Novo Nordisk Inc | 5 | $110 |
| Arthrex, Inc. | 1 | $106 |
| Sumitomo Pharma America, Inc. | 6 | $106 |
| ABIOMED | 1 | $101 |
Products named: VRAYLAR, JARDIANCE, General - Therapies, Symbravo, GEMTESA, Yeztugo, MOUNJARO, REXULTI.
Industry payments across CA — which companies pay providers there.
